Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(1):101–105. doi: 10.1038/bjc.1997.16

A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas.

A Rigg 1, D Cunningham 1, M Gore 1, M Hill 1, M O'Brien 1, M Nicolson 1, J Chang 1, M Watson 1, A Norman 1, A Hill 1, J Oates 1, H Moore 1, P Ross 1
PMCID: PMC2222694  PMID: 9000605

Abstract

Carcinoma of unknown primary site (CUPS) accounts for 5-10% of all malignancies. Forty patients with metastatic CUPS or advanced oesophagogastric/pancreatic adenocarcinomas were recruited. Eligibility included ECOG performance status 0-2, minimum life expectancy of 3 months and measurable disease. The regimen consisted of bolus intravenous 5 fluorouracil (5-FU) and leucovorin (20 mg m-2) days 1-5 and carboplatin (AUC5) on day 3. The leucovorin/carboplatin/5-FU (LCF) was repeated every 4 weeks. The starting dose of 5-FU was 350 mg m-2 day-1 with escalation to 370 and then 400 mg m-2 day -1 after the toxicity at the previous level had been assessed. The maximum tolerated dose (MTD) was defined as the dosage of 5-FU that achieved 60% grade 3/4 toxicity. In addition, objective and symptomatic responses, quality of life and survival were assessed. The MTD of 5-FU in the LCF regimen was 370 mg m-2. The predominant toxicity was asymptomatic marrow toxicity. The 350 mg m-2 level was then expanded. There were two toxic deaths due to neutropenic sepsis, one at 370 mg m-2 after one course and one at 350 mg m-2 after four courses. The objective response rate was 25% with one complete response (CR) and nine partial responses (PRs). The median duration of response was 3.4 months (range 1-10). The CR and eight of the nine PRs were in CUPS patients. Twelve patients developed progressive disease on LCF. Median survival for all 40 patients was 7.8 months (10 months median survival for those treated at 350 mg m-2). The majority of patients described a symptomatic improvement with LCF chemotherapy. The recommended dose of 5-FU for future studies is 350 mg m-2 combined with leucovorin 20 mg m-2 and carboplatin (AUC5).

Full text

PDF
101

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Calvert A. H., Harland S. J., Newell D. R., Siddik Z. H., Jones A. C., McElwain T. J., Raju S., Wiltshaw E., Smith I. E., Baker J. M. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982;9(3):140–147. doi: 10.1007/BF00257742. [DOI] [PubMed] [Google Scholar]
  2. Calvert A. H., Newell D. R., Gumbrell L. A., O'Reilly S., Burnell M., Boxall F. E., Siddik Z. H., Judson I. R., Gore M. E., Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748–1756. doi: 10.1200/JCO.1989.7.11.1748. [DOI] [PubMed] [Google Scholar]
  3. Copeland E. M., McBride C. M. Axillary metastases from unknown primary sites. Ann Surg. 1973 Jul;178(1):25–27. doi: 10.1097/00000658-197307000-00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hainsworth J. D., Johnson D. H., Greco F. A. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol. 1992 Jun;10(6):912–922. doi: 10.1200/JCO.1992.10.6.912. [DOI] [PubMed] [Google Scholar]
  5. Hainsworth J. D., Johnson D. H., Greco F. A. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Intern Med. 1988 Sep 1;109(5):364–371. doi: 10.7326/0003-4819-109-5-364. [DOI] [PubMed] [Google Scholar]
  6. Lenzi R., Raber M. N., Frost P., Schmidt S., Abbruzzese J. L. Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin. Eur J Cancer. 1993;29A(11):1634–1634. doi: 10.1016/0959-8049(93)90312-4. [DOI] [PubMed] [Google Scholar]
  7. Machover D., Goldschmidt E., Chollet P., Metzger G., Zittoun J., Marquet J., Vandenbulcke J. M., Misset J. L., Schwarzenberg L., Fourtillan J. B. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol. 1986 May;4(5):685–696. doi: 10.1200/JCO.1986.4.5.685. [DOI] [PubMed] [Google Scholar]
  8. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  9. Moertel C. G., Reitemeier R. J., Schutt A. J., Hahn R. G. Treatment of the patient with adenocarcinoma of unknown origin. Cancer. 1972 Dec;30(6):1469–1472. doi: 10.1002/1097-0142(197212)30:6<1469::aid-cncr2820300609>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  10. Mohit-Tabatabai M. A., Dasmahapatra K. S., Rush B. F., Jr, Ohanian M. Management of squamous cell carcinoma of unknown origin in cervical lymph nodes. Am Surg. 1986 Mar;52(3):152–154. [PubMed] [Google Scholar]
  11. Muggia F. M., Baranda J. Management of peritoneal carcinomatosis of unknown primary tumor site. Semin Oncol. 1993 Jun;20(3):268–272. [PubMed] [Google Scholar]
  12. Oken M. M., Creech R. H., Tormey D. C., Horton J., Davis T. E., McFadden E. T., Carbone P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649–655. [PubMed] [Google Scholar]
  13. Pavlidis N., Kosmidis P., Skarlos D., Briassoulis E., Beer M., Theoharis D., Bafaloukos D., Maraveyas A., Fountzilas G. Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. A Hellenic Cooperative Oncology Group Study. Ann Oncol. 1992 Sep;3(8):631–634. doi: 10.1093/oxfordjournals.annonc.a058290. [DOI] [PubMed] [Google Scholar]
  14. Poon M. A., O'Connell M. J., Wieand H. S., Krook J. E., Gerstner J. B., Tschetter L. K., Levitt R., Kardinal C. G., Mailliard J. A. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol. 1991 Nov;9(11):1967–1972. doi: 10.1200/JCO.1991.9.11.1967. [DOI] [PubMed] [Google Scholar]
  15. Raber M. N., Faintuch J., Abbruzzese J. L., Sumrall C., Frost P. Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. Ann Oncol. 1991 Jul;2(7):519–520. doi: 10.1093/oxfordjournals.annonc.a058007. [DOI] [PubMed] [Google Scholar]
  16. Richardson R. L., Schoumacher R. A., Fer M. F., Hande K. R., Forbes J. T., Oldham R. K., Greco F. A. The unrecognized extragonadal germ cell cancer syndrome. Ann Intern Med. 1981 Feb;94(2):181–186. doi: 10.7326/0003-4819-94-2-181. [DOI] [PubMed] [Google Scholar]
  17. Stewart J. F., Tattersall M. H., Woods R. L., Fox R. M. Unknown primary adenocarcinoma: incidence of overinvestigation and natural history. Br Med J. 1979 Jun 9;1(6177):1530–1533. doi: 10.1136/bmj.1.6177.1530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Strnad C. M., Grosh W. W., Baxter J., Burnett L. S., Jones H. W., 3rd, Greco F. A., Hainsworth J. D. Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. Ann Intern Med. 1989 Aug 1;111(3):213–217. doi: 10.7326/0003-4819-111-3-213. [DOI] [PubMed] [Google Scholar]
  19. van der Gaast A., Verweij J., Henzen-Logmans S. C., Rodenburg C. J., Stoter G. Carcinoma of unknown primary: identification of a treatable subset? Ann Oncol. 1990;1(2):119–122. doi: 10.1093/oxfordjournals.annonc.a057688. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES